APO Research
Talk to an analyst

APO RESEARCH · REPORT

Progressive Supranuclear Palsy

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Progressive Supranuclear Palsy Market Outlook and Growth Opportunities 2026

31 December 2025191 pages

Choose your research edition.

Industry ResearchProgressive Supranuclear Palsy Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Progressive Supranuclear Palsy Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Progressive Supranuclear Palsy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Progressive Supranuclear Palsy Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Progressive Supranuclear Palsy Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Progressive Supranuclear Palsy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Progressive Supranuclear Palsy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Progressive Supranuclear Palsy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Progressive Supranuclear Palsy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Progressive Supranuclear Palsy market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Progressive Supranuclear Palsy market include Novartis AG, Merck & Co., Inc., GlaxoSmithKline plc, Biogen Inc., Bristol Myers Squibb (BMS), AbbVie Inc., Acorda Therapeutics Inc., Teva Pharmaceutical Industries Ltd. and Cortice Biosciences, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Progressive Supranuclear Palsy market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Progressive Supranuclear Palsy and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Progressive Supranuclear Palsy revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Progressive Supranuclear Palsy market.

Progressive Supranuclear Palsy Segment by Company

Novartis AG

Merck & Co., Inc.

GlaxoSmithKline plc

Biogen Inc.

Bristol Myers Squibb (BMS)

AbbVie Inc.

Acorda Therapeutics Inc.

Teva Pharmaceutical Industries Ltd.

Cortice Biosciences, Inc.

Aton Pharma, Inc.

AlzProtect SAS

AB Science

Progressive Supranuclear Palsy Segment by Type

Late Stage

Clinical Trial

Early Stage

Others

Progressive Supranuclear Palsy Segment by Application

Clinics

Hospitals

Research Institutes

Others

Progressive Supranuclear Palsy Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Progressive Supranuclear Palsy status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Progressive Supranuclear Palsy key companies, revenue, market share, and recent developments.

3. To split the Progressive Supranuclear Palsy breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Progressive Supranuclear Palsy market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Progressive Supranuclear Palsy significant trends, drivers, influence factors in global and regions.

6. To analyze Progressive Supranuclear Palsy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Progressive Supranuclear Palsy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Progressive Supranuclear Palsy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Progressive Supranuclear Palsy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Progressive Supranuclear Palsy industry.

Chapter 3: Detailed analysis of Progressive Supranuclear Palsy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Progressive Supranuclear Palsy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Progressive Supranuclear Palsy in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Progressive Supranuclear Palsy Industry Trends Table 2. Progressive Supranuclear Palsy Industry Drivers Table 3. Progressive Supranuclear Palsy Industry Opportunities and Challenges Table 4. Progressive Supranuclear Palsy Industry Restraints Table 5. Global Progressive Supranuclear Palsy Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Progressive Supranuclear Palsy Revenue Share by Company (2021-2026) Table 7. Global Progressive Supranuclear Palsy Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Progressive Supranuclear Palsy Key Company Manufacturing Base & Headquarters Table 9. Global Progressive Supranuclear Palsy Company, Product Type & Application Table 10. Global Progressive Supranuclear Palsy Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Progressive Supranuclear Palsy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Late Stage Table 15. Significant Companies of Clinical Trial Table 16. Significant Companies of Early Stage Table 17. Significant Companies of Others Table 18. Global Progressive Supranuclear Palsy Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Progressive Supranuclear Palsy Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Progressive Supranuclear Palsy Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Progressive Supranuclear Palsy Sales Value Share by Type (2021-2026) Table 22. Global Progressive Supranuclear Palsy Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Clinics Table 24. Significant Companies of Hospitals Table 25. Significant Companies of Research Institutes Table 26. Significant Companies of Others Table 27. Global Progressive Supranuclear Palsy Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Progressive Supranuclear Palsy Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Progressive Supranuclear Palsy Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Progressive Supranuclear Palsy Sales Value Share by Application (2021-2026) Table 31. Global Progressive Supranuclear Palsy Sales Value Share by Application (2027-2032) Table 32. Global Progressive Supranuclear Palsy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Progressive Supranuclear Palsy Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Progressive Supranuclear Palsy Sales Value Share by Region (2021-2026) Table 35. Global Progressive Supranuclear Palsy Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Progressive Supranuclear Palsy Sales Value Share by Region (2027-2032) Table 37. Global Progressive Supranuclear Palsy Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Progressive Supranuclear Palsy Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Progressive Supranuclear Palsy Sales Value Market Share by Country (2021-2026) Table 40. Global Progressive Supranuclear Palsy Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Progressive Supranuclear Palsy Sales Value Market Share by Country (2027-2032) Table 42. Novartis AG Company Information Table 43. Novartis AG Business Overview Table 44. Novartis AG Progressive Supranuclear Palsy Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Novartis AG Progressive Supranuclear Palsy Product Portfolio Table 46. Novartis AG Recent Development Table 47. Merck & Co., Inc. Company Information Table 48. Merck & Co., Inc. Business Overview Table 49. Merck & Co., Inc. Progressive Supranuclear Palsy Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Merck & Co., Inc. Progressive Supranuclear Palsy Product Portfolio Table 51. Merck & Co., Inc. Recent Development Table 52. GlaxoSmithKline plc Company Information Table 53. GlaxoSmithKline plc Business Overview Table 54. GlaxoSmithKline plc Progressive Supranuclear Palsy Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. GlaxoSmithKline plc Progressive Supranuclear Palsy Product Portfolio Table 56. GlaxoSmithKline plc Recent Development Table 57. Biogen Inc. Company Information Table 58. Biogen Inc. Business Overview Table 59. Biogen Inc. Progressive Supranuclear Palsy Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Biogen Inc. Progressive Supranuclear Palsy Product Portfolio Table 61. Biogen Inc. Recent Development Table 62. Bristol Myers Squibb (BMS) Company Information Table 63. Bristol Myers Squibb (BMS) Business Overview Table 64. Bristol Myers Squibb (BMS) Progressive Supranuclear Palsy Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Bristol Myers Squibb (BMS) Progressive Supranuclear Palsy Product Portfolio Table 66. Bristol Myers Squibb (BMS) Recent Development Table 67. AbbVie Inc. Company Information Table 68. AbbVie Inc. Business Overview Table 69. AbbVie Inc. Progressive Supranuclear Palsy Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. AbbVie Inc. Progressive Supranuclear Palsy Product Portfolio Table 71. AbbVie Inc. Recent Development Table 72. Acorda Therapeutics Inc. Company Information Table 73. Acorda Therapeutics Inc. Business Overview Table 74. Acorda Therapeutics Inc. Progressive Supranuclear Palsy Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Acorda Therapeutics Inc. Progressive Supranuclear Palsy Product Portfolio Table 76. Acorda Therapeutics Inc. Recent Development Table 77. Teva Pharmaceutical Industries Ltd. Company Information Table 78. Teva Pharmaceutical Industries Ltd. Business Overview Table 79. Teva Pharmaceutical Industries Ltd. Progressive Supranuclear Palsy Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Teva Pharmaceutical Industries Ltd. Progressive Supranuclear Palsy Product Portfolio Table 81. Teva Pharmaceutical Industries Ltd. Recent Development Table 82. Cortice Biosciences, Inc. Company Information Table 83. Cortice Biosciences, Inc. Business Overview Table 84. Cortice Biosciences, Inc. Progressive Supranuclear Palsy Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Cortice Biosciences, Inc. Progressive Supranuclear Palsy Product Portfolio Table 86. Cortice Biosciences, Inc. Recent Development Table 87. Aton Pharma, Inc. Company Information Table 88. Aton Pharma, Inc. Business Overview Table 89. Aton Pharma, Inc. Progressive Supranuclear Palsy Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Aton Pharma, Inc. Progressive Supranuclear Palsy Product Portfolio Table 91. Aton Pharma, Inc. Recent Development Table 92. AlzProtect SAS Company Information Table 93. AlzProtect SAS Business Overview Table 94. AlzProtect SAS Progressive Supranuclear Palsy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. AlzProtect SAS Progressive Supranuclear Palsy Product Portfolio Table 96. AlzProtect SAS Recent Development Table 97. AB Science Company Information Table 98. AB Science Business Overview Table 99. AB Science Progressive Supranuclear Palsy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. AB Science Progressive Supranuclear Palsy Product Portfolio Table 101. AB Science Recent Development Table 102. Research Programs/Design for This Report Table 103. Authors List of This Report Table 104. Secondary Sources Table 105. Primary Sources List of Figures Figure 1. Progressive Supranuclear Palsy Product Image Figure 2. Global Progressive Supranuclear Palsy Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Progressive Supranuclear Palsy Market Size (2021-2032) & (US$ Million) Figure 4. Global Progressive Supranuclear Palsy Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Late Stage Image Figure 8. Clinical Trial Image Figure 9. Early Stage Image Figure 10. Others Image Figure 11. Global Progressive Supranuclear Palsy Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Progressive Supranuclear Palsy Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Progressive Supranuclear Palsy Sales Value Share by Type (2021-2032) Figure 14. Clinics Image Figure 15. Hospitals Image Figure 16. Research Institutes Image Figure 17. Others Image Figure 18. Global Progressive Supranuclear Palsy Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Progressive Supranuclear Palsy Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Progressive Supranuclear Palsy Sales Value Share by Application (2021-2032) Figure 21. Global Progressive Supranuclear Palsy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Progressive Supranuclear Palsy Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Progressive Supranuclear Palsy Sales Value (2021-2032) & (US$ Million) Figure 24. North America Progressive Supranuclear Palsy Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Progressive Supranuclear Palsy Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Progressive Supranuclear Palsy Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Progressive Supranuclear Palsy Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Progressive Supranuclear Palsy Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Progressive Supranuclear Palsy Sales Value (2021-2032) & (US$ Million) Figure 30. South America Progressive Supranuclear Palsy Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Progressive Supranuclear Palsy Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Progressive Supranuclear Palsy Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Late Stage
  • Clinical Trial
  • Early Stage
  • Others
Applications
  • Clinics
  • Hospitals
  • Research Institutes
  • Others
Companies covered
  • Novartis AG
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Biogen Inc.
  • Bristol Myers Squibb (BMS)
  • AbbVie Inc.
  • Acorda Therapeutics Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Cortice Biosciences, Inc.
  • Aton Pharma, Inc.
  • AlzProtect SAS
  • AB Science

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Progressive Supranuclear Palsy Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Progressive Supranuclear Palsy Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Progressive Supranuclear Palsy Market Dynamics
  1. 2.1 Progressive Supranuclear Palsy Industry Trends
  2. 2.2 Progressive Supranuclear Palsy Industry Drivers
  3. 2.3 Progressive Supranuclear Palsy Industry Opportunities and Challenges
  4. 2.4 Progressive Supranuclear Palsy Industry Restraints
3 Progressive Supranuclear Palsy Market by Company
  1. 3.1 Global Progressive Supranuclear Palsy Company Revenue Ranking in 2025
  2. 3.2 Global Progressive Supranuclear Palsy Revenue by Company (2021-2026)
  3. 3.3 Global Progressive Supranuclear Palsy Company Ranking (2024-2026)
  4. 3.4 Global Progressive Supranuclear Palsy Company Manufacturing Base and Headquarters
  5. 3.5 Global Progressive Supranuclear Palsy Company Product Type and Application
  6. 3.6 Global Progressive Supranuclear Palsy Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Progressive Supranuclear Palsy Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Progressive Supranuclear Palsy Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Progressive Supranuclear Palsy Market by Type
  1. 4.1 Progressive Supranuclear Palsy Type Introduction
  2. 4.1.1 Late Stage
  3. 4.1.2 Clinical Trial
  4. 4.1.3 Early Stage
  5. 4.1.4 Others
  6. 4.2 Global Progressive Supranuclear Palsy Sales Value by Type
  7. 4.2.1 Global Progressive Supranuclear Palsy Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Progressive Supranuclear Palsy Sales Value by Type (2021-2032)
  9. 4.2.3 Global Progressive Supranuclear Palsy Sales Value Share by Type (2021-2032)
5 Progressive Supranuclear Palsy Market by Application
  1. 5.1 Progressive Supranuclear Palsy Application Introduction
  2. 5.1.1 Clinics
  3. 5.1.2 Hospitals
  4. 5.1.3 Research Institutes
  5. 5.1.4 Others
  6. 5.2 Global Progressive Supranuclear Palsy Sales Value by Application
  7. 5.2.1 Global Progressive Supranuclear Palsy Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Progressive Supranuclear Palsy Sales Value by Application (2021-2032)
  9. 5.2.3 Global Progressive Supranuclear Palsy Sales Value Share by Application (2021-2032)
6 Progressive Supranuclear Palsy Regional Value Analysis
  1. 6.1 Global Progressive Supranuclear Palsy Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Progressive Supranuclear Palsy Sales Value by Region (2021-2032)
  3. 6.2.1 Global Progressive Supranuclear Palsy Sales Value by Region: 2021-2026
  4. 6.2.2 Global Progressive Supranuclear Palsy Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Progressive Supranuclear Palsy Sales Value (2021-2032)
  7. 6.3.2 North America Progressive Supranuclear Palsy Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Progressive Supranuclear Palsy Sales Value (2021-2032)
  10. 6.4.2 Europe Progressive Supranuclear Palsy Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Progressive Supranuclear Palsy Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Progressive Supranuclear Palsy Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Progressive Supranuclear Palsy Sales Value (2021-2032)
  16. 6.6.2 South America Progressive Supranuclear Palsy Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Progressive Supranuclear Palsy Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Progressive Supranuclear Palsy Sales Value Share by Country, 2025 VS 2032
7 Progressive Supranuclear Palsy Country-level Value Analysis
  1. 7.1 Global Progressive Supranuclear Palsy Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Progressive Supranuclear Palsy Sales Value by Country (2021-2032)
  3. 7.2.1 Global Progressive Supranuclear Palsy Sales Value by Country (2021-2026)
  4. 7.2.2 Global Progressive Supranuclear Palsy Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Progressive Supranuclear Palsy Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Progressive Supranuclear Palsy Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Progressive Supranuclear Palsy Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis AG
  2. 8.1.1 Novartis AG Company Information
  3. 8.1.2 Novartis AG Business Overview
  4. 8.1.3 Novartis AG Progressive Supranuclear Palsy Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis AG Progressive Supranuclear Palsy Product Portfolio
  6. 8.1.5 Novartis AG Recent Developments
  7. 8.2 Merck & Co., Inc.
  8. 8.2.1 Merck & Co., Inc. Company Information
  9. 8.2.2 Merck & Co., Inc. Business Overview
  10. 8.2.3 Merck & Co., Inc. Progressive Supranuclear Palsy Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck & Co., Inc. Progressive Supranuclear Palsy Product Portfolio
  12. 8.2.5 Merck & Co., Inc. Recent Developments
  13. 8.3 GlaxoSmithKline plc
  14. 8.3.1 GlaxoSmithKline plc Company Information
  15. 8.3.2 GlaxoSmithKline plc Business Overview
  16. 8.3.3 GlaxoSmithKline plc Progressive Supranuclear Palsy Revenue and Gross Margin (2021-2026)
  17. 8.3.4 GlaxoSmithKline plc Progressive Supranuclear Palsy Product Portfolio
  18. 8.3.5 GlaxoSmithKline plc Recent Developments
  19. 8.4 Biogen Inc.
  20. 8.4.1 Biogen Inc. Company Information
  21. 8.4.2 Biogen Inc. Business Overview
  22. 8.4.3 Biogen Inc. Progressive Supranuclear Palsy Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Biogen Inc. Progressive Supranuclear Palsy Product Portfolio
  24. 8.4.5 Biogen Inc. Recent Developments
  25. 8.5 Bristol Myers Squibb (BMS)
  26. 8.5.1 Bristol Myers Squibb (BMS) Company Information
  27. 8.5.2 Bristol Myers Squibb (BMS) Business Overview
  28. 8.5.3 Bristol Myers Squibb (BMS) Progressive Supranuclear Palsy Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Bristol Myers Squibb (BMS) Progressive Supranuclear Palsy Product Portfolio
  30. 8.5.5 Bristol Myers Squibb (BMS) Recent Developments
  31. 8.6 AbbVie Inc.
  32. 8.6.1 AbbVie Inc. Company Information
  33. 8.6.2 AbbVie Inc. Business Overview
  34. 8.6.3 AbbVie Inc. Progressive Supranuclear Palsy Revenue and Gross Margin (2021-2026)
  35. 8.6.4 AbbVie Inc. Progressive Supranuclear Palsy Product Portfolio
  36. 8.6.5 AbbVie Inc. Recent Developments
  37. 8.7 Acorda Therapeutics Inc.
  38. 8.7.1 Acorda Therapeutics Inc. Company Information
  39. 8.7.2 Acorda Therapeutics Inc. Business Overview
  40. 8.7.3 Acorda Therapeutics Inc. Progressive Supranuclear Palsy Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Acorda Therapeutics Inc. Progressive Supranuclear Palsy Product Portfolio
  42. 8.7.5 Acorda Therapeutics Inc. Recent Developments
  43. 8.8 Teva Pharmaceutical Industries Ltd.
  44. 8.8.1 Teva Pharmaceutical Industries Ltd. Company Information
  45. 8.8.2 Teva Pharmaceutical Industries Ltd. Business Overview
  46. 8.8.3 Teva Pharmaceutical Industries Ltd. Progressive Supranuclear Palsy Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Teva Pharmaceutical Industries Ltd. Progressive Supranuclear Palsy Product Portfolio
  48. 8.8.5 Teva Pharmaceutical Industries Ltd. Recent Developments
  49. 8.9 Cortice Biosciences, Inc.
  50. 8.9.1 Cortice Biosciences, Inc. Company Information
  51. 8.9.2 Cortice Biosciences, Inc. Business Overview
  52. 8.9.3 Cortice Biosciences, Inc. Progressive Supranuclear Palsy Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Cortice Biosciences, Inc. Progressive Supranuclear Palsy Product Portfolio
  54. 8.9.5 Cortice Biosciences, Inc. Recent Developments
  55. 8.10 Aton Pharma, Inc.
  56. 8.10.1 Aton Pharma, Inc. Company Information
  57. 8.10.2 Aton Pharma, Inc. Business Overview
  58. 8.10.3 Aton Pharma, Inc. Progressive Supranuclear Palsy Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Aton Pharma, Inc. Progressive Supranuclear Palsy Product Portfolio
  60. 8.10.5 Aton Pharma, Inc. Recent Developments
  61. 8.11 AlzProtect SAS
  62. 8.11.1 AlzProtect SAS Company Information
  63. 8.11.2 AlzProtect SAS Business Overview
  64. 8.11.3 AlzProtect SAS Progressive Supranuclear Palsy Revenue and Gross Margin (2021-2026)
  65. 8.11.4 AlzProtect SAS Progressive Supranuclear Palsy Product Portfolio
  66. 8.11.5 AlzProtect SAS Recent Developments
  67. 8.12 AB Science
  68. 8.12.1 AB Science Company Information
  69. 8.12.2 AB Science Business Overview
  70. 8.12.3 AB Science Progressive Supranuclear Palsy Revenue and Gross Margin (2021-2026)
  71. 8.12.4 AB Science Progressive Supranuclear Palsy Product Portfolio
  72. 8.12.5 AB Science Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst